An ADVI expert from the Federal and State Policy team discussed some unanswered questions to CMS’ Inflation Reduction Act (IRA). Becca Davison shared with AIS Health that the rebates should have minimal effects, if any, on premiums for Medicare Advantage (MA) plans with prescription drug coverage and stand-alone Prescription Drug Plans (PDPs), given the information that is currently available, however, drugmakers may try to recoup their losses through more aggressive commercial plan rebate strategies.

Read more on the IRA and Becca’s predictions in AIS Health.